New Psoriasis Pill Gains FDA Approval

The U.S. Food and Drug Administration has approved Icotyde, a new once-daily oral medication for psoriasis developed by Johnson & Johnson. This approval marks a significant advancement in treatment options for patients suffering from the chronic skin condition. The introduction of Icotyde is expected to intensify competition within the psoriasis treatment market, particularly challenging established therapies. This development offers a new therapeutic avenue and potentially improved patient outcomes in managing psoriasis.